http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9fc9bede51216e5cb1c0d0f185ed01a1
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Signoretti |
| name | Sabina Signoretti |
| given-name | Sabina |
| organization-name | Department of Pathology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA. Brigham and Women’s Hospital , Department of Pathology, Boston, MA , USA Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA Authors' Affiliations: 1Department of Pathology and Immunology, Baylor College of Medicine; 2Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas; 3Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles; 4Department of Pathology and Laboratory Medicine; 5Center for Comparative Medicine, University of California, Davis, Davis, California; 6Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick; 7Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore; 8Virology & Cellular Immunology Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland; Departments of 9Pathology and 10Medical Oncology, Brigham and Women's Hospital; Departments of 11Pathology and 12Medical Oncology, Center for Molecular Oncologic Pathology, 13Department of Medical Oncology, Dana-Fa Authors' Affiliations: 1Hematology Division, 2Department of Pathology, Brigham & Women's Hospital; 3Department of Medicine, Harvard Medical School; 4Department of Cancer Biology, Dana-Farber Cancer Institute; 5Harvard Stem Cell Institute, Boston; and 6Broad Institute of Harvard and MIT, Cambridge, Massachusetts; Authors' Affiliations: 1Hematology Division, 2Department of Pathology, Brigham & Women's Hospital; 3Department of Medicine, Harvard Medical School; 4Department of Cancer Biology, Dana-Farber Cancer Institute; 5Harvard Stem Cell Institute, Boston; and 6Broad Institute of Harvard and MIT, Cambridge, Massachusetts Department of Adult Oncology (D.W., S.S., P.S., D.L., N.B., N.C., M.L.) Massachusetts 02115; Dana-Farber Cancer Institute, and Department of Pathology (S.S., M.L.) Brigham and Women’s Hospital Harvard Medical School Boston, Massachusetts 02115 Harvard Medical School, Boston, MA, USA; Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 2Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts and Department of Pathology Brigham and Women's Hospital Boston Massachusetts; Harvard Medical School Boston Massachusetts Authors' Affiliations: Departments of 1Biostatistics and Computational Biology, and 2Medical Oncology; 3Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 4Department of Biostatistics, Harvard School of Public Health; 5Department of Pathology; 6Translational Medicine Division, Brigham and Women's Hospital, Boston; 7Broad Institute of Harvard and MIT, Cambridge, Massachusetts; 8Sidney Kimmel Cancer Center; 9Department of Pathology, Johns Hopkins University, Baltimore, Maryland; 10Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York; and 11Hospital del Mar Research Institute-IMIM, Barcelona; and 12Hospital Parc Tauli, Sabadell, Spain Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115;; Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 1Department of Medical Oncology, Dana-Farber Cancer Institute; Departments of; 3Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; and Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA 3Brigham and Women's Hospital, Boston, Massachusetts. 1Kidney Cancer Center, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Department of Medical Oncology Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, USA Authors' Affiliations: 1Dana-Farber Cancer Institute;; 2Brigham and Women's Hospital; and; 3Harvard Medical School, Boston, Massachusetts Department of Adult Oncology, Dana-Farber Cancer Institute; Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215;; Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115; Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 12Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Beth Israel Deaconess Medical Center, Boston, MA, USA Authors' Affiliations: 1Division of Hematology-Oncology and Cancer Biology, 2Department of Radiology, Beth Israel Deaconess Medical Center, 3Department of Pathology, Brigham and Women's Hospital, and 4Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Authors' Affiliations: 1Division of Hematology-Oncology and Cancer Biology, 2Department of Radiology, Beth Israel Deaconess Medical Center, 3Department of Pathology, Brigham and Women's Hospital, and 4Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts Department of Adult Oncology, Dana-Farber Cancer Institute; Departments of Pathology and Medicine Department of Pathology, Brigham and Women’s Cancer Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts Authors' Affiliations: 1Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, 2Department of Pathology, Brigham and Women's Hospital, and 3Department of Biostatistics, Dana-Farber Cancer Institute, Boston, Massachusetts Medical Oncology, Dana–Farber Cancer Institute, Boston, MA 02115; and 5Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.; 6Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 8Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Dana-Farber Cancer Institute, Boston, MA 11Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 7Department of Pathology, Dana Farber Cancer Center, Boston, Massachusetts. Department of Medical Oncology, Dana–Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115; From the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Cancer Registry of Norway, Oslo, Norway; Dana-Farber Cancer Institute and Dana-Farber/Harvard Cancer Center; and Department of Epidemiology, Harvard School of Public Health, Boston, MA. Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115; Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115 Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, 3Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; Departments of 4Medicine and 5Pathology, Brigham and Women's Hospital, Harvard Medical School; 6Division of Hematology/Oncology, Massachusetts General Hospital, Boston; 7Broad Institute of Harvard and MIT; 8Department of Biology, Whitehead Institute for Biomedical Research; 9Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts; and 10Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York; Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, 3Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; Departments of 4Medicine and 5Pathology, Brigham and Women's Hospital, Harvard Medical School; 6Division of Hematology/Oncology, Massachusetts General Hospital, Boston; 7Broad Institute of Harvard and MIT; 8Department of Biology, Whitehead Institute for Biomedical Research; 9Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts; and 10Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 2Brigham and Women's Hospital;; 4Renal Cancer Program, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts 1Medical Oncology and Departments of; 3Pathology and 1Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.; 9Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02215, USA.; Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA. 7Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA Division of Signal Transduction, Beth Israel Deaconess Medical Center and Department of Systems Biology, Harvard Medical School, Boston, MA 02115; Department of Pathology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA 02115; and Division of Cancer Biology, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, MA 02115 3Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Department of Pathology Brigham and Women's Hospital Harvard Medical School Boston MA USA 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; 3Harvard Medical School, Boston, Massachusetts.; 10Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. 5Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. Laurence Albiges, Wanling Xie, Rana R. McKay, Andre P. Fay, Guillermo de Velasco, Sabina Signoretti, and Toni K. Choueiri, Dana-Farber Cancer Institute; Wanling Xie, Rana R. McKay, Mark A. Preston, Eunyoung Cho, Sabina Signoretti, and Toni K. Choueiri, Brigham and Women's Hospital; Laurence Albiges, Wanling Xie, Rana R. McKay, Andre P. Fay, Guillermo de Velasco, Eunyoung Cho, David F. McDermott, Sabina Signoretti, and Toni K. Choueiri, Harvard Medical School; Mark A. Preston and Kathryn M. Wilson,... 3Brigham and Women's Hospital, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115; Department of Medical Oncology, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; Department of Cell Biology, Harvard Medical School, Boston, MA 02115; and Broad Institute, Massachusetts Institute of Technology, Harvard University, and the Whitehead Institute for Biomedical Research, Cambridge, MA 02141 1Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.; 2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; 4Kidney Cancer Program, Dana-Farber Harvard Cancer Center, Boston, Massachusetts. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA Toni K. Choueiri, Susanna Jacobus, Joaquim Bellmunt, Angela Qu, Edward C. Stack, Sabina Signoretti, Meghara Walsh, Graeme Steele, Michelle Hirsch, Christopher J. Sweeney, Mary-Ellen Taplin, Adam S. Kibel, Katherine M. Krajewski, Philip W. Kantoff, Robert W. Ross, and Jonathan E. Rosenberg, Dana-Farber Cancer Institute and Brigham and Women's Hospital; Christopher Tretter, Lahey Clinic, Burlington; Glenn J. Bubley, Beth Israel Deaconess Medical Center, Boston, MA; Leonard J. Appleman, University of... Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02215; 1Department of Medical Oncology, Dana-Farber Cancer Institute, and Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School; 2Department of Cancer Biology, Dana-Farber Cancer Institute; and 3Departments of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School and; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115 10Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. Sabina Signoretti and Abdallah Flaifel, Brigham and Women’s Hospital; Sabina Signoretti, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Ying-Bei Chen and Victor E. Reuter, Memorial Sloan Kettering Cancer Center; and Victor E. Reuter, Weill Cornell Medical College, New York, NY 5Preclinical Murine Pharmacogenetics Facility, Beth Israel Deaconess Medical Center;; 9Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Department of Pathology, Harvard Medical School, 02215, Boston, Massachusetts, USA;Department of Medical Oncology, Dana-Farber Cancer Institute, 02215, Boston, Massachusetts, USA;Department of Pathology, Brigham and Women's Hospital, 02215, Boston, Massachusetts, USA 1Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.; 3Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Authors' Affiliations: Departments of 1Medical Oncology and 2Cancer Biology, Dana-Farber Cancer Institute; Departments of 3Medicine and 4Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston; 5Broad Institute, Cambridge, Massachusetts; 6Howard Hughes Medical Institute, Chevy Chase, Maryland; Authors' Affiliations: Departments of 1Medical Oncology and 2Cancer Biology, Dana-Farber Cancer Institute; Departments of 3Medicine and 4Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston; 5Broad Institute, Cambridge, Massachusetts; 6Howard Hughes Medical Institute, Chevy Chase, Maryland Department of Pathology and Kidney Cancer Program, Dana Farber, Boston, MA, USA 1Department of Pathology, Brigham and Women's Hospital and Department of Medical Oncology, Dana-Farber Cancer Institute; 5Pathology, Brigham and Women’s Hospital, Boston, Massachusetts; Departments of; 7Pathology, Harvard Medical School, Boston, Massachusetts; and 1Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.; 9Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 From the Department of Medical Oncology (J.M., Y.A.M., W.G.K.) and Department of Biostatistics and Computational Biology (D.N.), Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass; Division of Cardiovascular Medicine (J.M., J.S., R.L.), Division of Nephrology, Department of Medicine (D.M.C.) and Pathology (R.F.P., S.S.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass; and Howard Hughes Medical Institute, Chevy Chase, Md (W.G.K.). Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA Department of Pathology Brigham and Women's Hospital Boston Massachusetts 5Renal Cancer Program, Dana-Farber/Harvard Cancer Center Boston, Massachusetts Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, Boston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland; Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, Boston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland Renal Cancer Program, Dana Farber/Harvard Cancer Center, Boston, MA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA. Authors' Affiliations: 1Dana-Farber Cancer Institute; 2Brigham and Women's Hospital; 3Harvard Medical School, Boston, Massachusetts; 4GlaxoSmithKline, Collegeville, Pennsylvania; 5Memorial Sloan-Kettering Cancer Center, New York, New York; and 6Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas; Authors' Affiliations: 1Dana-Farber Cancer Institute; 2Brigham and Women's Hospital; 3Harvard Medical School, Boston, Massachusetts; 4GlaxoSmithKline, Collegeville, Pennsylvania; 5Memorial Sloan-Kettering Cancer Center, New York, New York; and 6Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas; Authors' Affiliations: 1Dana-Farber Cancer Institute; 2Brigham and Women's Hospital; 3Harvard Medical School, Boston, Massachusetts; 4GlaxoSmithKline, Collegeville, Pennsylvania; 5Memorial Sloan-Kettering Cancer Center, New York, New York; and 6Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas 2Dana-Farber/Harvard Cancer Institute; Brigham and Women's Hospital, Harvard Medical School;; 4Dana-Farber/Harvard Cancer Central Renal Cancer Program, Boston, MA; and Departments of |
Incoming Links
Showing number of triples: 1 to 369 of 369.